A Fresh Coat: Innovation in Excipients - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

A Fresh Coat: Innovation in Excipients
Sophisticated excipient development, especially for coatings, is staying on top of new challenges and meeting expanding industry needs.

Pharmaceutical Technology
Volume 32, Issue 11, pp. 46-56

Figure 1: Grafted polymers, such as polyethylene glycol with polyvinyl alcohol, provide flexibility and reduce spray-coat time. (IMAGES ARE COURTESY OF BASF.)
Improving polymers to reduce time, energy, and material is thus an important research area for coating formulators. BASF's instant-release coating material is a chemically new polymer (as opposed to a new mixture or a new coprocessed polymer) made of well-known polyethylene glycol (PEG) and polyvinyl alcohol (PVA) covalently bonded as a graft polymer, in which the sidechains of PVA are chemically bonded to a PEG backbone ("Kollicoat IR," see Figure 1). "Because PEG is part of the polymer and because it is chemically bound to PVA, it cannot migrate to the core nor escape the surface, and remains an extremely flexible film for all types of tablets," says Folttmann. Kollicoat IR can be diluted to concentration of up to 30%, so the spray process requires less water and a shorter period of time. As Folttmann observes, the challenge, as with many new excipients, is that companies are reluctant to try a formulation that has not been reviewed by regulators or monographed in a pharmacopeia. This year, Kollicoat IR received a draft monograph in PharmEuropa, which is expected to become final in the next year. (Visit the online exclusive article regarding the International Pharmaceutical Excipients Council's new efforts to reduce regulation hurdles for new excipients).

A statistical strategy. When ISP entered the pharmaceutical coating segment of the industry in 2005, it set out to apply a statistical design of experiment (DOE) to create databases that would facilitate the design of coating formulations and to ascertain the ideal processing conditions for a given platform. "This approach has not been exploited to a high degree," says Stuart Porter, senior science fellow of film coating technology at ISP. "When you look at FDA's quality-by-design inititiatives, clearly using a statisitical DOE is one of the preferred approaches to creating the knowledge about the product. We have taken that same approach and created knowledge about our component of that product, which is the coating system."

The key variables of the database are the various properties of the coating systems, including mechanical strength, flexibility, adhesion, disintegration, dissolution, film roughness or smoothness, gloss, and cost. All responses are measured for each formulation in the DOE and the database is created as the ratio of ingredients and the types of ingredients in the formulation are manipulated. The database allows minimum values to be set in one area that needs to be achieved and how much the formulation can change to maintain those minimum values while improving the value in a different characteristic that is also important.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here